Authors
Jiayi Li, Jing Li, Lin Yu
Published in
Neoplasma. Oct 06, 2026. Epub Oct 06, 2026.
Abstract
Gliomas, the most prevalent primary malignant brain tumors, are characterized by highly invasive growth patterns. Emerging evidence indicates that long non-coding RNAs are essential for regulating key oncogenic pathways. This study focuses on lncRNA LAMTOR5 antisense RNA AS1 (LAMTOR5-AS1, also known as SLC16A4-AS1), seeking to elucidate its regulatory functions in gliomas and assess its potential as a prognostic biomarker. LAMTOR5-AS1 expression in normal brain tissues and glioma samples was assessed using quantitative real-time polymerase chain reaction (qRT-PCR). The Cancer Genome Atlas (TCGA) glioma dataset was mined for COX regression and Kaplan-Meier survival analyses to check LAMTOR5-AS1 correlation with clinical outcomes. The competing endogenous RNA (ceRNA) function of LAMTOR5-AS1 targeting miR-4653-5p was determined using anti-AGO2 immunoprecipitation assays and dual-luciferase reporter assays. The oncogenic properties of LAMTOR5-AS1 in glioma were systematically detected through in vivo and in vitro phenotype experiments. The results revealed that glioma tissues had higher levels of LAMTOR5-AS1 expression, which had a positive correlation with glioma grade and indicated a poor outcome. LAMTOR5-AS1 knocking down inhibits the malignant progression of glioma cells. Mechanistically, it was demonstrated that the LAMTOR5-AS1 regulates TCF7 level via sponging miR-4653-5p, which was correlated with the malignant progression of glioma cells. To conclude, through the miR-4653-5p/TCF7 axis, LAMTOR5-AS1 serves as ceRNA and modulates the progression of glioma.
PMID:
42834663
Bibliographic data and abstract were imported from PubMed on 06 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 9
- Comments 0